Vertex Wins FDA Approval for New Cystic Fibrosis Drug
- Posted by ISPE Boston
- On October 23, 2019
The FDA has approved Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor) for the treatment of cystic fibrosis (CF) in people ages 12 years and older who have the most common CF-causing mutation. With this approval, for the first time, approximately 6,000 people with CF ages 12 years and older who have one F508del mutation and one minimal function mutation […]
Read More